StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3091% above fair value
$57.23+0.53 (+0.93%)

Close on Nov 13, 2026Market cap $11.08BP/E 150.6Yield –

BioMarin Pharmaceutical operating margin

Operating margin is operating income as a percentage of revenue.

BioMarin Pharmaceutical's operating margin for the twelve months ending Jun 30, 2026 was 4.4%. For fiscal 2025 it was 12.7%, against 17.0% the year before. The highest annual figure on record is 17.0% in fiscal 2024.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202512.7%−4.3
FY2024Dec 31, 202417.0%+9.3
FY2023Dec 31, 20237.7%−0.0
FY2022Dec 31, 20227.7%+12.1
FY2021Dec 31, 2021-4.5%−2.1
FY2020Dec 31, 2020-2.3%+3.6
FY2019Dec 31, 2019-5.9%+2.4
FY2018Dec 31, 2018-8.3%−7.2
FY2017Dec 31, 2017-1.1%+70.8
FY2016Dec 31, 2016-71.9%−59.5
FY2015Dec 31, 2015-12.4%−0.0
FY2014Dec 31, 2014-12.4%+16.0
FY2013Dec 31, 2013-28.4%−6.4
FY2012Dec 31, 2012-22.0%−14.3
FY2011Dec 31, 2011-7.7%−7.8
FY2010Dec 31, 20100.1%−4.9
FY2009Dec 31, 20095.1%−8.3
FY2008Dec 31, 200813.4%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202611.2%−22.3
Q1 FY2026Mar 31, 202616.9%−13.1
Q4 FY2025Dec 31, 2025-5.1%−26.7
Q3 FY2025Sep 30, 2025-6.0%−21.3
Q2 FY2025Jun 30, 202533.5%+16.6
Q1 FY2025Mar 31, 202530.0%+16.4
Q4 FY2024Dec 31, 202421.6%+17.4
Q3 FY2024Sep 30, 202415.3%+10.0
Q2 FY2024Jun 30, 202416.9%+5.9
Q1 FY2024Mar 31, 202413.6%+3.2
Q4 FY2023Dec 31, 20234.2%+6.7
Q3 FY2023Sep 30, 20235.3%+5.7
Q2 FY2023Jun 30, 202311.0%+3.7
Q1 FY2023Mar 31, 202310.5%−16.0
Q4 FY2022Dec 31, 2022-2.4%+12.2
Q3 FY2022Sep 30, 2022-0.5%+12.5
Q2 FY2022Jun 30, 20227.3%+5.0
Q1 FY2022Mar 31, 202226.4%+21.3
Q4 FY2021Dec 31, 2021-14.6%−3.3
Q3 FY2021Sep 30, 2021-13.0%−1.3
Q2 FY2021Jun 30, 20212.3%+11.9
Q1 FY2021Mar 31, 20215.2%−15.7
Q4 FY2020Dec 31, 2020-11.4%−9.4
Q3 FY2020Sep 30, 2020-11.7%−12.6
Q2 FY2020Jun 30, 2020-9.5%+1.1
Q1 FY2020Mar 31, 202020.9%+34.4
Q4 FY2019Dec 31, 2019-2.0%+8.8
Q3 FY2019Sep 30, 20190.9%+4.9
Q2 FY2019Jun 30, 2019-10.7%−3.9
Q1 FY2019Mar 31, 2019-13.5%−1.6
Q4 FY2018Dec 31, 2018-10.8%−27.0
Q3 FY2018Sep 30, 2018-4.0%+0.1
Q2 FY2018Jun 30, 2018-6.8%+5.5
Q1 FY2018Mar 31, 2018-11.9%−5.2
Q4 FY2017Dec 31, 201716.2%+46.1
Q3 FY2017Sep 30, 2017-4.1%+17.4
Q2 FY2017Jun 30, 2017-12.2%–
Q1 FY2017Mar 31, 2017-6.7%–
Q4 FY2016Dec 31, 2016-29.9%–
Q3 FY2016Sep 30, 2016-21.5%–

More BioMarin Pharmaceutical figures

See a number that looks wrong?